NL
CRSP icon

NVWM LLC’s CRISPR Therapeutics CRSP Stock Holding History

NVWM LLC’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-11,322
Closed -$710K – 480
2022
Q1 		$710K Sell
11,322
-189
-2% -$11.9K 0.23% 145
2021
Q4 		$872K Hold
11,511
– – 0.27% 136
2021
Q3 		$1.29M Buy
11,511
+83
+0.7% +$10.4K 0.46% 60
2021
Q2 		$1.85M Buy
11,428
+321
+3% +$39K 0.66% 39
2021
Q1 		$1.35M Sell
11,107
-66
-0.6% -$9.97K 0.54% 50
2020
Q4 		$1.71M Buy
11,173
+242
+2% +$28.6K 0.71% 45
2020
Q3 		$915K Buy
10,931
+172
+2% +$15.3K 0.43% 73
2020
Q2 		$790K Hold
10,759
– – 0.43% 74
2020
Q1 		$456K Buy
10,759
+805
+8% +$41.6K 0.32% 96
2019
Q4 		$606K Sell
9,954
-329
-3% -$18K 0.36% 90
2019
Q3 		$422K Buy
+10,283
New +$491K 0.26% 127

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

NVWM LLC's CRSP Position: Q2 2022 in Review

NVWM LLC sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 11,322 shares — an estimated $710K sold.

NVWM LLC first reported a position in CRSP in Q3 2019 and held it in 11 quarters. The position peaked at $1.85M in Q2 2021. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • NVWM LLC reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • NVWM LLC sold 11,322 CRISPR Therapeutics shares in Q2 2022, an estimated $710K.
  • NVWM LLC first reported a position in CRISPR Therapeutics in Q3 2019 and held it in 11 quarters.
  • NVWM LLC's CRISPR Therapeutics position peaked at $1.85M in Q2 2021.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on NVWM LLC's 13F filing for Q2 2022, filed 4 Aug 2022.